The addition of all-trans retinoic acid to pembrolizumab conferred benefit to patients with metastatic melanoma, according to results of a phase 1b/phase 2 trial published in Clinical Cancer Research.
Clinical Trials
Broad Immune Activity Is Observed With Sotigalimab Combo in Frontline Melanoma
Findings from a phase 1/2 trial showed that sotigalimab plus pembrolizumab led to antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.
Trial Receives FDA Green Light to Proceed Evaluating EVX-01, Keytruda Combo in Metastatic Melanoma
A phase 2 trial evaluating EVX-01 plus Keytruda (pembrolizumab) in patients with metastatic melanoma may continue, the FDA said.
Adjuvant Pembrolizumab Improves QOL vs Ipilimumab or HDI in Resected Melanoma
Treatment with adjuvant pembrolizumab (Keytruda) resulted in favorable quality-of-life (QOL) outcomes vs high-dose interferon ? 2b (HDI) or ipilimumab (Yervoy) in patients with resected melanoma at high risk for relapse, according to the results of the secondary analysis of the phase 3 SWOG S1404 trial (NCT02506153).